-
- Valiltramiprosate Reduced ARIA Rates In APOE4/4 With Early AD: Results Of Phase 3 APOLLOE4 Trial And CAA Implications [Board No. Monday-0098]
-
Board no. Monday-0098
Earvin Liang1, Susan Abushakra, MD1, David Watson2, Jerome Barakos3, Anton P. Porsteinsson4, Marwan Sabbagh, MD5, Emer MacSweeney, BSc (Hons), MRCP, FRCR6, Sharon Cohen7, Mercè Boada8, Patrick Kesslak, PhD1, Susan Flint1, Aidan Power, MD1, John A. Hey, PhD1, Martin Tolar, MD PHD1;
1Alzheon, Framingham, MA, USA, 2Alzheimer’s Research and Treatment Center, Wellington, FL, USA, 3Clario Inc, San Mateo, CA, USA, 4University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, 5Barrow Neurological Institute, Neurology, Phoenix, AZ, USA, 6ReCognition Health, London, United Kingdom, 7Toronto Memory Program, Toronto, ON, Canada, 8Ace Alzheimer Center, Barcelona, SpainTypes
Enter Note
Go to previous page in this tab
Session